AptarGroup price target raised to $168 from $163 at Wells Fargo

Wells Fargo raised the firm’s price target on AptarGroup to $168 from $163 and keeps an Overweight rating on the shares. The firm favors AptarGroup going into the Q2 print, given primary exposure to pharma end markets plus minimal exposure to healthcare destocking. Wells believes AptarGroup’s Pharma remains well positioned to benefit from new product launches, conversion into nasal delivery, and organic investment. Visibility in the beauty segment is admittedly low, but improving sentiment in Europe bodes well for second half of the year recovery, the firm adds.